Form 4: Jade Biosciences Director Acquires Stock Options Under Fairmount Arrangement

Christopher W. Cain, a director of Jade Biosciences, acquired stock options for 23,017 shares, which he holds on behalf of Fairmount Funds Management LLC.

Summary

• Christopher W. Cain, a director at Jade Biosciences, acquired options to purchase 23,017 shares of common stock on April 29, 2025.
• The exercise price of these options is $10.14 per share.
• The options vest fully on the earlier of April 29, 2026, or the date of the next annual meeting of the Issuer's stockholders, contingent upon continued service to the Issuer.
• Cain holds these options under an arrangement with Fairmount Funds Management LLC, and disclaims beneficial ownership, as any proceeds from the options will be turned over to Fairmount.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. It simply reports the acquisition of stock options.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track potential shifts in ownership and sentiment.

Related Party Transactions

• The reporting person, Christopher W. Cain, has an arrangement with Fairmount Funds Management LLC, indicating a related party relationship.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders, aligning management's interests with theirs.

Key Dates

Keywords

stock options, Form 4, beneficial ownership, Jade Biosciences, Christopher Cain, Fairmount Funds